Social Media Ideas for Drug Development

<![CDATA[The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang]]>

<![CDATA[The Next Chapter in Metabolic Drug Development]]>

<![CDATA[Where GLP-1 Development May be Headed]]>

From Discovery to Development

The articles in this eBook examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and...

ADC Developmentfrom Concept to Clinic

This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics. The post ADC Developmentfrom Concept to Clinic appeared first on GEN - Genetic E...

<![CDATA[The Most Surprising Development in GLP-1s]]>

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

<![CDATA[MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews]]&g...

FDA launches pilot program to speed up early US drug research

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicin...

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to p...

“The way this works is… at a very high level, making a new drug that's used by many people takes longer, is more expensive, and takes as many people as building the biggest skyscra...

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to “determine next steps” for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

HHS kicks off new programs to speed clinical trials as Chinese competition looms

The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.

FDA Opens Applications for New Pilot to Shorten Drug Approval Times: What Sponsors Need to Know

Earlier this month, FDA opened applications for a new Expedited Investigational New Drug (IND) Pilot Program (the “Program”), an initiative launched under HHS Operation TrialBlazer...

AI Drug Discovery Hits a New Bottleneck: Experimental Validation

Sponsored content brought to you by Artificial intelligence is dramatically accelerating early drug discovery. Models can screen chemical space, predict structures, optimize proper...

<![CDATA[Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data]]>

Advancing AAV Development: From Production to Performance

In this GEN Learning Lab, our expert panelists Guangping Gao, PhD, and Thomas Quinn will explore critical steps in the AAV workflow that influence vector quality and downstream exp...

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

PRNewswireMumbai (Maharashtra) [India], October 1: Piramal Pharma Solutions ('PPS'), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal...

Designing Peptide Screens to Generate Knowledge, Not Just Hits

The strongest binder from a primary screen is not necessarily the best drug starting point. Peptide discovery campaigns should capture molecular architecture, biological context, t...

Streamlining stable cell line development from the start

Discover how early optimization in stable cell line development accelerates timelines and reduces downstream bottlenecks. The post Streamlining stable cell line development from th...

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Developer acquires global rights to Parkinson’s drug in deal worth $300M

In a deal that could be worth more than $300 million, a Korean biotech has acquired exclusive global rights to develop and commercialize 1ST Biotherapeutics‘ 1ST-104, an oral treat...

<![CDATA[What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?]]>

Syngene Expands Integrated Drug Development and Manufacturing Services with BMS

The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center, Synge...

Beyond Animal Testing: FDA's 2026 Framework for Fit-for-Purpose NAMs

In September 2026, FDA took another significant step toward integrating new approach methodologies, or NAMs, into drug development by issuing a Direct Final Rule on Nonclinical Tes...